Phaseline

Targets › NTCP

NTCP (Hepatic sodium/bile acid cotransporter): drug programs, companies and trials

1 program from 1 company in 4 trials: 2 Phase 3, 2 Phase 2; Infectious disease; next expected readout Jun 2027.

As a major transporter of conjugated bile salts from plasma into the hepatocyte, it plays a key role in the enterohepatic circulation of bile salts necessary for the solubilization and absorption of dietary fat and fat-soluble vitamins. It is strictly dependent on the extracellular presence of sodium. (UniProt, Q14973)

Open in Phaseline: the race on NTCP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mirum PharmaceuticalsBrelovitug (BJT-778)
NTCP (sodium taurocholate cotransporting polypeptide) inhibitor
NTCPPhase 3Chronic Hepatitis D Infection; Chronic Hepatitis DJun 2027

Conditions

Chronic Hepatitis D Infection (3) Chronic Hepatitis D (1)

Modalities

antibody (1)

Companies

Mirum Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.